Inclusion Criteria:

- Locally advanced carcinoma of the pancreas

- Arterial invasion or encasement

- Invasion/encasement of the portomesenteric veins

- Patients who have been previously denied operation

- Obstructive jaundice must be drained with a polyethylene biliary stent or surgical
bypass prior to beginning treatment.

- White blood cell count > 3500 per ml and platelet count > 100,000 per ml

- Serum creatinine ≤ 1.5 mg/dl

- Bilirubin ≤ 1.5

- ECOG performance status < 2

Exclusion Criteria:

- Prior chemotherapy, radiotherapy, or investigational agents for pancreatic cancer

- Evidence of distant metastasis or malignant lymphadenopathy

- Concurrent malignancies

- History of allergic reactions to celecoxib or to sulfa drugs

- No non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, magnesium or aluminum
containing antacids, fluconazole or lithium may be administered within 5 days of
study entry, during the study and for the 30 days following the completion of all
study treatments.

- Pregnant women and lactating women

- Uncontrolled or serious intercurrent illness

- HIV-positive patients receiving combination antiretroviral therapy